Developing a genetically encoded serotonin sensor for hemodynamic brain imaging

Summarise with VIRAT
Authors: K. Ryndia, N. Jain, Robert Ohlendorf
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Serotonin, acting as a neurotransmitter, hormone, and neuromodulator, affects mood, sleep, and cognition. Its dysregulation contributes to psychiatric, neurological, and somatic disorders1. Although serotonin sensors were developed before, genetically encodable tool that enables molecular signaling mapping on a brain-wide level is lacking2,3. To overcome this limitation, we designed a genetically encodable serotonin Activatable Vasoprobe for Analyte Targeting (Sero-AVATar4) that enables serotonergic processes to be monitored in living mammals using functional magnetic resonance imaging (fMRI). Methods: For the Sero-AVATar design, we inserted the vasoactive piuitary adenylate cyclase activating peptide (PACAP38) into different regions of serotonin-binding protein X513OpuBC. All sensor variants were screened in vitro using a cell-based luminescence assays for their activity, ligand sensitivity and selectivity. The optimized sensor was applied in vivo to validate its performance and serotonin detection ability in the brain of living rodents using T2*-weighted MRI, generating signal-change maps. For this, adeno-associated virus (AAV) encoding Sero-AVATar was stereotaxically injected into the caudate putamen of Sprague-Dawley rats. After 4 to 6 weeks, the animals were imaged using a 14.1 T preclinical MRI scanner while activating Sero-AVATar via intracranial injection of serotonin. Results/Discussion: We developed Sero-AVATar by coupling serotonin-induced activation of a binding protein to PACAP38 exposure, which then activates receptors on vascular smooth muscle cells, causing hemodynamic signal changes in fMRI (Fig.1A). Various variants were screened in vitro using high-throughput bioluminescence assays (Fig.1B). The half maximal effective dose (EC50) of optimized Sero-AVATar showed a shift in the presence of serotonin, confirming serotonin-induced sensor activation (Fig.1C). Serotonin dose-response analysis revealed sensor activation with an EC50 of ~0.7 mM (Fig.1D). Sero-AVATar also responded to a similar dopamine dose (Fig.1E), reflecting the chemical similarity of monoamines. In vivo, 150 µM serotonin induced a clear fMRI signal increase in the AAV-preinjected regions compared to PBS control. Histology confirmed that fMRI signal changes coincide with AAV-induced sensor expression (Fig.2A,B). Future work will focus on developing sensor with enhanced serotonin specificity. Conclusion: In this work, we developed Sero-AVATar, a genetically encodable serotonin sensor capable of detecting µM-level serotonin using fMRI. This sensor enables minimally invasive, brain-wide imaging of neurochemical activity and can provide needed insight into the serotonergic mechanism in mammalian brain under healthy and pathological conditions.

Fields of Study & Subjects

Advanced Fluorescence Microscopy Techniques Advanced MRI Techniques and Applications Neurotransmitter Receptor Influence on Behavior

Publication details

Journal / source
MPG.PuRe (Max Planck Society)
Publication date
1 January 2026
Language
EN